Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.

  title={Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.},
  author={Jacques Gaudreault and David Fei and Jeriza Rusit and Pamela Suboc and Vanessa Shiu},
  journal={Investigative ophthalmology & visual science},
  volume={46 2},
PURPOSE Ranibizumab (rhuFab V2; Lucentis, Genentech, South San Francisco, CA) is a humanized monoclonal antibody fragment designed to bind all forms of VEGF, thereby blocking vessel permeability and angiogenesis in neovascular age-related macular degeneration. This study evaluated the pharmacokinetic (PK) and serum bioavailability of ranibizumab after a single intravitreal (ITV) or intravenous (IV) dose in cynomolgus monkeys. METHODS Monkeys received ranibizumab as either a bilateral ITV dose… CONTINUE READING
Highly Influential
This paper has highly influenced 11 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
172 Citations
38 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 172 extracted citations


Publications referenced by this paper.
Showing 1-10 of 38 references

Pharmacokinetics and retinal distribution of AMD rhufab V2 after intravitreal administration in rabbits

  • J Gaudreault, W Webb, M Van Hoy
  • AAPS Pharm Sci
  • 1999
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…